Related Experiment Video

Updated: Feb 7, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K

Metformin inhibits non-small cell lung cancer via lncRP11-242D8.1

Xinmin Tian1, Zhixiong Qiao2, Yan Ma3

  • 1Department of Cardiac and Major Vascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China.

Archives of Biochemistry and Biophysics
|February 5, 2026
PubMed
Abstract

Insights

Metformin, a diabetes drug, shows promise in treating non-small cell lung cancer (NSCLC) by increasing lncRP11-242D8.1 long non-coding RNA. This mechanism helps reduce inflammation and boost cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality.
  • Long non-coding RNAs (lncRNAs) play critical roles in NSCLC development and progression.
  • Metformin, a widely used antidiabetic drug, has demonstrated potential anticancer properties.

Purpose of the Study:

  • To investigate the inhibitory effect of metformin on NSCLC.
  • To explore the role of metformin in modulating the expression of lncRP11-242D8.1 in NSCLC.
  • To elucidate the molecular mechanisms underlying metformin's anticancer effects in NSCLC.

Main Methods:

  • Assessment of inflammation and apoptosis using immunofluorescence, RT-qPCR, and ELISA.
  • In vitro evaluation of metformin's effects on NSCLC cell lines (H1299) via CCK8, scratch wound healing, Transwell, colony formation, and flow cytometry assays.
  • Combined bioinformatics analysis and molecular experiments to determine the interplay between metformin and lncRP11-242D8.1.

Main Results:

  • Low expression of lncRP11-242D8.1 correlates with increased inflammation, decreased apoptosis, and poor prognosis in NSCLC.
  • Metformin treatment in the H1299 cell model reversed these trends, indicating an inhibitory effect on NSCLC progression.
  • Upregulation of lncRP11-242D8.1 by metformin was observed, suggesting its involvement in metformin's therapeutic action.

Conclusions:

  • Metformin exerts therapeutic effects in NSCLC by upregulating lncRP11-242D8.1 expression.
  • The upregulation of lncRP11-242D8.1 by metformin leads to the inhibition of inflammation and promotion of apoptosis in NSCLC.
  • This study provides a novel mechanistic insight into metformin's anticancer activity, suggesting its potential as a clinical treatment strategy for NSCLC.
Keywords:
ApoptosisInflammatory factorsLncRNAMetforminNon small cell lung cancer

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

417
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K